Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Non-randomized, Open-label, Mono-centric, Cohort Study on the Absorption of Oral Rivaroxaban in Patients With a Cervical Spinal Cord Injury

Trial Profile

Prospective, Non-randomized, Open-label, Mono-centric, Cohort Study on the Absorption of Oral Rivaroxaban in Patients With a Cervical Spinal Cord Injury

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Acute coronary syndromes; Atrial fibrillation; Cardiovascular disorders; Coronary thrombosis; Deep vein thrombosis; Embolism; Peripheral arterial disorders; Pulmonary embolism; Stroke; Thromboembolism; Thrombosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 17 Jan 2019 Planned End Date changed from 1 Dec 2019 to 7 Dec 2018.
    • 17 Jan 2019 Planned primary completion date changed from 1 Jun 2019 to 7 Dec 2018.
    • 17 Jan 2019 Status changed from recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top